AbbVie has reported strong preliminary results from its pivotal Phase 3 ECLIPSE trial, showing that atogepant delivers faster migraine relief than placebo. The company has also submitted an application to the European Medicines Agency (EMA) seeking expanded approval for the acute treatment of migraine.
Phase 3 ECLIPSE: Strong Early Relief
The ECLIPSE study tested atogepant 60 mg for the acute treatment of migraine in adults with or without aura. The design was rigorous: randomized, double-blind, placebo-controlled, and spread across multiple countries.
Key results:
- 24.3% of patients achieved pain freedom at two hours vs. 13.1% with placebo.
- Atogepant met its primary and key secondary endpoints.
- The first 12 of 16 endpoints showed statistical significance.
- Freedom from most bothersome symptoms at two hours also reached p < 0.0001.
These results will be presented at the European Headache Congress in Lisbon.
Why These Results Matter?
Migraine remains one of the world’s most disabling neurological disorders. Many patients still lack fast, flexible, and reliable treatment options. AbbVie believes atogepant can fill this gap.
“These results represent a step forward toward a pain-free future,”
- Dr. Primal Kaur, Senior Vice President at AbbVie.
If approved, the therapy would offer a new acute option for adults across Europe.
Safety Profile: Consistent and Predictable
Atogepant’s safety profile in the 24-week trial aligned with earlier prophylaxis studies.
Most common adverse events (≥2%):
- Nasopharyngitis (4.6%)
- Upper respiratory infections (2.3%)
No new safety concerns emerged. This consistency strengthens the case for expanded authorization.
Understanding Migraine: A Global Burden
Migraine affects 14% of the global population. It strikes most often between ages 25 and 55 and affects women more than men.
Typical symptoms include:
- Severe throbbing pain
- Sensitivity to light and sound
- Nausea
- Temporary loss of daily functioning
The socioeconomic cost is massive. In Europe alone, migraine accounts for a 1.2%–2% GDP loss, driven largely by reduced productivity—especially in unpaid work.
Inside the ECLIPSE Study
The 24-week trial enrolled 1,223 adults across Europe, the UK, Japan, China, South Korea, and Taiwan.
Study design highlights:
- Adults aged 18–75 with 2–8 migraine attacks in three months
- Four-attack treatment sequence using atogepant or placebo
- Primary endpoint: pain relief two hours after dosing
- Secondary endpoint: absence of most bothersome symptoms
- Open-label atogepant treatment from weeks 16 to 24
ClinicalTrials.gov identifier: NCT06241313
What Is Atogepant?
Atogepant is a CGRP receptor antagonist. CGRP levels rise sharply during migraine attacks, making it a proven therapeutic target.
Key facts:
- Taken orally once daily
- Approved in over 60 countries for migraine prophylaxis
- Marketed as AQUIPTA® in the EU and QULIPTA® in the U.S., Canada, Israel, and Puerto Rico
EU Indication and Safety Highlights for AQUIPTA®
Indication: Prophylaxis of migraine in adults with at least four migraine days per month.
Contraindications: Hypersensitivity to atogepant or any excipients.
Precautions: Not recommended in severe liver dysfunction. Not recommended during pregnancy or without contraception.
Common side effects:
- Nausea (9%)
- Constipation (8%)
- Fatigue or drowsiness (5%)
Full EU SmPC available on the EMA website.
AbbVie’s Broader Commitment to Migraine Care
AbbVie continues to invest in migraine research, education, and patient support.
The company aims to improve access, address unmet needs, and enable better everyday functioning for patients.
AbbVie’s mission spans multiple therapeutic areas including neuroscience, immunology, oncology, ophthalmology, and aesthetics.
